Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19.
Increased recognition of parvovirus B19 (B19), an erythrovirus, as a significant human pathogen that causes fetal loss and severe disease in immunocompromised patients has resulted in intensive efforts to understand the pathogenesis of B19-related disease, to improve diagnostic strategy that is deployed to detect B19 infection and blood-product contamination and, finally, to elucidate the nature of the cellular immune response that is elicited by the virus in diverse patient cohorts. It is becoming clear that at least three related erythrovirus strains (B19, A6/K71 and V9) are circulating in the general population and that viral entry into target cells is mediated by an expanding range of cellular receptors, including P antigen and beta-integrins. Persistent infection by B19 is emerging as a contributory factor in autoimmune disease, a hypothesis that is constrained by the detection of B19 in the skin of apparently healthy individuals. B19 infection during pregnancy may account for thousands of incidences of fetal loss per annum in Europe, North America and beyond, yet there is currently only minimal screening of pregnant women to assess serological status, and thereby risk of infection, upon becoming pregnant. Whilst major advances in diagnosis of B19 infection have taken place, including standardization of serological and DNA-based detection methodologies, blood donations that are targeted at high-risk groups are only beginning to be screened for B19 IgG and DNA as a means of minimizing exposure of at-risk patients to the virus. It is now firmly established that a Th1-mediated cellular immune response is mounted in immunocompetent individuals, a finding that should contribute to the development of an effective vaccine to prevent B19 infection in selected high-risk groups, including sickle-cell anaemics.
Corcoran
Amanda
A
National Institute for Cellular Biotechnology, Department of Biology, National University of Ireland Maynooth, Maynooth, Co. Kildare, Ireland.
Doyle
Sean
S
National Institute for Cellular Biotechnology, Department of Biology, National University of Ireland Maynooth, Maynooth, Co. Kildare, Ireland.
D000741:Anemia, Aplastic / Q000821:virology; D000914:Antibodies, Viral / Q000097:blood; D001168:Arthritis / Q000821:virology; D001782:Blood Donors; D001803:Blood Transfusion / Q000592:standards; D004279:DNA, Viral / Q000097:blood; D016731:Erythema Infectiosum / Q000175:diagnosis; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D010322:Parvoviridae Infections / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D016732:Parvovirus B19, Human / Q000302:isolation & purification / Q000472:pathogenicity / Q000502:physiology; D016133:Polymerase Chain Reaction / Q000379:methods; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000276:immunology
D000914:Antibodies, Viral; D004279:DNA, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M